Core Framework & Diagram What Is Immune AI?
July 23, 2026Core Framework & Diagram What Are Immune Predictive Models?
July 23, 2026When AI begins understanding the language of the immune system, medicine enters a new era
—— Immune AI: from antibody design to clinical decisions — how artificial intelligence is reshaping immune medicine.
I. AlphaFold: when AI learned to read the folding language of proteins
In 2021, DeepMind released AlphaFold2, achieving an epoch-making breakthrough in protein structure prediction — it can predict a protein's three-dimensional structure from amino acid sequences with accuracy approaching experimental resolution, and the speed is millions of times faster than traditional experimental methods (X-ray crystallography, cryo-EM). In immunology, the significance of this breakthrough is profound: antibody-antigen interaction prediction — understanding how antibodies bind to viruses or tumor antigens is the foundation of antibody drug and vaccine design. AlphaFold lets researchers quickly predict antibody-antigen complex structures without experiments, accelerating antibody optimization design; neoantigen MHC presentation prediction — MHC molecule (HLA) binding with neoantigen peptides is the prerequisite for the immune system to recognize cancerous cells. AI models (like NetMHCpan, MHCflurry) can predict which peptide segments can bind to specific HLA molecules from protein sequences, the core computational tool for individualized tumor vaccine neoantigen screening.
AlphaFold3 (released 2024) introduced prediction capabilities for protein-nucleic acid and protein-small molecule complexes, beginning to address TCR-pMHC structural prediction, opening new possibilities for computational understanding of T cell function. The 2024 releases of AlphaFold3 and RoseTTAFold All-Atom further extended prediction capabilities to antibody-antigen complexes, protein-DNA-RNA complexes, and protein-small molecule (drug molecule) binding prediction, pushing AI structural prediction to a new stage fully covering biomolecular interactions.
|
AlphaFold transformed 'understanding protein folding' — the so-called biological 'holy grail' — from a field requiring decades and billions of dollars of experiments, into a seconds-long computational problem. Almost every question in immunology requiring 'understanding how proteins interact' was fundamentally accelerated. |
2. AI and TCR libraries: finding meaning among millions of sequences
The TCR library is one of the highest-information-density data in the immune system — every person's peripheral blood has millions to hundreds of millions of different TCR sequences, each representing one T cell clone's antigen recognition capability. Extracting meaningful information from this vast amount of sequences is a standard AI-strength problem. Main AI application directions: TCR-pMHC specificity prediction — given a TCR sequence, predicting which peptide-MHC complex it can recognize (what antigen it 'specializes in'). This is extremely important for identifying tumor-specific T cell clones from tumor patients' TCR libraries and designing individualized ACT therapy. Representative AI models: ERGO, NetTCR, TITAN. Public sequence identification — different individuals often produce T cell clones containing similar sequence characteristics ('public sequences') against the same pathogen (like CMV, EBV, flu virus). AI can systematically identify these public sequences from large-scale TCR library data, building TCR-antigen pairing databases (like VDJdb, McPAS-TCR). Immune aging TCR markers — by comparing TCR diversity and clonal composition across different age groups, AI can identify TCR characteristics of immune aging.
3. AI-driven antibody discovery and optimization
Antibody drugs (monoclonal antibodies, bispecific antibodies, etc.) are one of the most important drug categories in biopharmaceuticals. Traditional antibody discovery relies on animal immunization, hybridoma technology, phage display, and other experimental methods — taking months to years, extremely high cost. AI is fundamentally changing antibody discovery speed and strategy: large language models for antibody design — treating protein sequences as 'language,' language models trained on hundreds of millions of antibody sequences (like ProtTrans, ESM series) can predict functional properties of given antibody sequences, generate high-affinity new sequences, and optimize existing antibodies' stability and immunogenicity. Companies like Absci, BigHat Biosciences, and Generate Biomedicines are commercializing these AI tools.
Structure-function relationship learning — combining AlphaFold's structural prediction and large amounts of experimental data, AI can learn relationships between antibody structural characteristics (amino acid combinations in CDR regions) and binding affinity, guiding rational antibody engineering modifications. Humanized antibody optimization — antibodies from animals (like mice) need to be 'humanized' before use in humans — replacing amino acids different from human immunoglobulins, avoiding human antibody immune reactions. AI can quickly predict which position replacements can maximize humanization of antibody sequences while maintaining affinity, accelerating this process.
4. Clinical prediction models: from data to decisions
In tumor immunotherapy clinical practice, there's a long-standing problem troubling doctors: with the same treatment, which patients will respond and which won't? This isn't just an academic question — immunotherapy (especially CAR-T and hematopoietic stem cell transplantation) has considerable risks and side effects. If treatment response probability can be more accurately predicted before treatment, patients who are unlikely to respond can avoid unnecessary treatment risks. AI clinical prediction models, by integrating multidimensional input data (genomic data, transcriptomic data, clinical characteristics, treatment history), train models predicting treatment response or disease progression. Representative applications: immune checkpoint inhibitor response prediction — AI models integrating TMB, PD-L1 expression, MSI status, and tumor microenvironment composition have higher prediction accuracy than single biomarkers; CAR-T CRS risk prediction — pre-treatment immune state data (IL-6 baseline, ferritin level, etc.) combined with AI models can predict which patients will develop severe CRS before treatment; post-transplant GVHD early warning — AI models based on early blood immune monitoring data can warn high-risk patients weeks before GVHD clinical symptoms appear.
|
AI clinical prediction models don't replace doctor judgment — they compress patterns distilled from hundreds of thousands of patient datasets into a tool that can give reference opinions in seconds. Doctor experience + AI data = better than either used alone. |
5. Generative AI and immunology: from analysis to creation
Generative AI's applications in immunology represent AI's upgrade from 'analyzing existing data' to 'creating new molecules and strategies.' Key generative AI applications: de novo design of new antibodies — not optimizing from existing antibody libraries, but directly using AI to generate entirely new antibody sequences targeting specific antigens. This 'from scratch design' can explore antibody structural spaces that natural evolution never reached, possibly discovering new antibodies with higher affinity or better characteristics; AI-designed neoantigen peptide vaccines — beyond finding natural neoantigens from patient tumor mutations, AI is being used to design 'optimal antigen peptide sequences' — not a real mutation, but an idealized peptide sequence most likely to be presented by specific HLA and most easily recognized by T cells; large language models (LLM) in immunology literature understanding — models like ChatGPT, trained specifically on immunology literature, can assist researchers quickly extracting key findings from hundreds of papers and generating research hypotheses. One of generative AI's most representative achievements in drug design: Insilico Medicine's AI-designed anti-fibrosis drug received FDA clinical trial approval in 2024 — the first drug completely designed by AI (target identification + molecule generation) to enter clinical trials.
Frequently Asked Questions